Mycophenolic acid
Product Code: AG-CN2-0419
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0419-M100 | 100 mg | £70.00 |
Quantity:
| AG-CN2-0419-M500 | 500 mg | £250.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+20°C
Documents
Further Information
Alternate Names/Synonyms:
MPA; NSC 129185; Ly 68618; Mycophenolate
Appearance:
White to off-white solid.
CAS:
24280-93-1
Class:
9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08,GHS09
Handling Advice:
Keep cool and dry.
Hazards:
H302, H341, H360D, H410
InChi:
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChiKey:
HPNSFSBZBAHARI-RUDMXATFSA-N
Long Description:
Chemical. CAS: 24280-93-1. Formula: C17H20O6. MW: 320.3. Isolated from Penicillium brevi-compactum. Antibiotic. Shows antiviral, antifungal and antitumor properties. Immunosuppressive drug used to prevent rejection in organ transplantation, rheumatoid arthritis, and psoriasis. Potent reversible inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), leading to depletion of GMP and interruption of the de novo synthesis of purine nucleotides necessary for B and T lymphocyte proliferation. Inhibits the type II IMPDH isoform (IMPDH-2) 5-fold more potently compared to type I isoform. Inhibits RNA and DNA synthesis. Inducible nitric oxide synthase (iNOS/NOS II) inhibitor. Apoptosis and necrosis inducer. Novel type of inhibitor against RNA guanylyltransferases. Inhibits TNF-alpha-stimulated MAPK/NF-kappaB and ROS generation.
MDL:
MFCD00036814
Molecular Formula:
C17H20O6
Molecular Weight:
320.3
Package Type:
Vial
PG:
III
Precautions:
P273, P281, P301, P312, P308, P313, P391, P405
Product Description:
Antibiotic [1]. Shows antiviral, antifungal and antitumor properties [1, 2]. Immunosuppressive drug used to prevent rejection in organ transplantation, rheumatoid arthritis, and psoriasis [3-6, 13]. Potent reversible inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH), leading to depletion of GMP and interruption of the de novo synthesis of purine nucleotides necessary for B and T lymphocyte proliferation [7, 8]. Inhibits the type II IMPDH isoform (IMPDH-2) 5-fold more potently compared to type I isoform [11]. Inhibits RNA and DNA synthesis [13]. Inducible nitric oxide synthase (iNOS/NOS II) inhibitor [8, 10]. Apoptosis and necrosis inducer [9, 12]. Novel type of inhibitor against RNA guanylyltransferases [14]. Inhibits TNF-alpha-stimulated MAPK/NF-kappaB and ROS generation [15]. Autophagy suppressor. Broad-spectrum antiviral compound with inhibitory activity against different coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2, cause of COVID-19. It binds to the active site of SARS-CoV-2 papain-like protease (PLpro) possibly inhibiting viral replication.
Purity:
>98% (HPLC, TLC)
Signal word:
Danger
SMILES:
COC1=C(C)C2=C(C(=O)OC2)C(O)=C1CC=C(/C)CCC(O)=O
Solubility Chemicals:
Soluble in DMSO, methanol or ethanol. Insoluble in water.
Source / Host:
Isolated from Penicillium brevi-compactum.
Transportation:
Excepted Quantity
UN Nummer:
UN 3077
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
Mycophenolic acid: antiviral and antitumor properties: R.H. Williams, et al.; J. Antibiot. 21, 463 (1968) | Mycophenolic acid: an anti-cancer compound with unusual properties: S.B. Carter, et al.; Nature 223, 848 (1969) | Treatment of psoriasis with oral mycophenolic acid: E.L. Jones, et al.; J. Invest. Dermatol. 65, 537 (1975) | Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depeletion: E.M. Eugui, et al.; Scand. J. Immunol. 33, 161 (1991) | New small molecule immunosuppressants for transplantation: review of essential concepts: R.E. Morris; J. Heart Lung Transplant. 12, 275 (1993) | Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil: A.C. Allison & E.M. Eugui; Immunol. Rev. 136, 5 (1993) | Mechanisms of action of mycophenolic acid: A.C. Allison, et al.; Ann. N. Y. Acad. Sci. 696, 63 (1993) (Review) | Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells: M. Senda, et al.; Transplantation 60, 1143 (1995) | Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines: R.G. Cohn, et al.; Transplantation 68, 411 (1999) | Inducible nitric oxide synthase inhibition by mycophenolic acid: D.J. Miljkovic, et al.; Mini Rev. Med. Chem. 4, 741 (2004) | Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection: A.C. Allison & E.M. Eugui; Transplantation 80, S181 (2005) | The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal: B. Chaigne-Delalande, et al.; J. Immunol. 181, 7630 (2008) | Mycophenolic acid in rheumatology: mechanisms of action and severe adverse events: G. Zizzo, et al.; Reumatismo 62, 91 (2010) (Review) | Virtual high-throughput screening identifies mycophenolic acid as a novel RNA capping inhibitor: M. Tremblay-Letourneau, et al.; PLoS One 6, e24806 (2011) | Mycophenolic acid attenuates the tumour necrosis factor alpha-mediated proinflammatory response in endothelial cells by blocking the MAPK/NF-kappaB and ROS pathways: W. Olejarz, et al.; Eur. J. Clin. Invest. 44, 54 (2014) | Thiopurine analogs and mycophenolic acid synergistically inhibit the papainlike protease of Middle East respiratory syndrome coronavirus: K.W. Cheng, et al.; Antiviral Res. 115, 9 (2015) | High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses: L. Shen, et al.; J. Virol. 93, e00023-19 (2019) | Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV): A. Elfiky & N.S. Ibrahim; Biophys. Infect. Dis. (Preprint) (2020)
Related Products
| Product Name | Product Code | Supplier | Ionomycin (free acid) | AG-CN2-0416 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionomycin . calcium salt | AG-CN2-0418 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ascomycin (high purity) | AG-CN2-0420 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||